Pamplona Therapeutics

Pioneering Next-Generation Therapeutics:
AI Meets Protein Degradation
Redefining Medicine view more

SCROLL DOWN

Who We Are ?

Pamplona is dedicated to improving human health
by addressing unmet major clinical needs.

Founded in 2022, Pamplona Therapeutics is an innovative drug research and development company committed to tackling significant unmet medical needs and advancing global health.

Pamplona Therapeutics utilizes its proprietary ASTRIDE^® algorithm platform, which is built on protein structure and Al technology, to accelerate the design of novel therapeutics. Leveraging targeted protein degradation technology, we are committed to developing best-in-class and first-in-class innovative drugs for oncology and autoimmune diseases.

Vision

Transform healthcare through groundbreaking innovation

Mission Statement

Develop safe and effective therapeutics to improve patients' lives

Our Pipeline

Our R&D pipeline is strategically focused on high-impact therapeutic areas, including autoimmune diseases and oncology, with substantial market potential and distinct competitive advantages.

We have advanced our core program, P001, to identify multiple preclinical candidates showing strong in vitro and in vivo performance across several indications, including potential first-in-class and best-in-class molecules.